Grabar Law Office Investigates Claims on Behalf of Long-term Shareholders of Beta Bionics, Inc. (BBNX)

Grabar Law Office is investigating claims on behalf of shareholders of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. If you purchased Beta Bionics, Inc. (NASDAQ: BBNX) shares prior to July 30, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/bbnx-shareholder-investigation/ , contact Joshua Grabar at [email protected] , or call 267-507-6085 to learn more.

According to a recently filed securities fraud class action complaint, it is alleged that Beta Bionics, Inc. (NASDAQ: BBNX), through certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) the FDA had raised numerous serious issues with the iLet device itself, namely that the device was malfunctioning and dosing patients with dangerously high levels of insulin, causing hypoglycemic events; (ii) contrary to defendants' assertions that the complaints back-filed with the FDA pursuant to the Form 483 were of no moment and entirely benign, they instead numbered in the thousands and included hundreds of life-threatening events requiring significant medical intervention; and (iii) the FDA was not satisfied with Beta Bionics' response to the issue, as Beta Bionics had utterly failed to implement any meaningful corrective actions.

Specifically, in October 2025, Beta Bionics, Inc. (NASDAQ: BBNX), through certain of its officers, disclosed that it had received a Form 483 from the U.S. Food and Drug Administration ("FDA") raising concerns about iLet insulin delivery device. Yet, it is alleged, Beta Bionics and certain of its offices stressed that the letter had nothing to do with the safety or efficacy of the device itself, and that the FDA had only taken issue with Beta Bionics' interpretation of which customer complaints needed to be reported to the FDA, such that Beta Bionics would have to back-file some additional minor customer complaints in which no medical intervention was required.

The underlying class action complaint further alleges that defendants assured investors that Beta Bionics was swiftly implementing the FDA's required changes to its complaint reporting system, and accordingly that they did not "foresee any ongoing challenge with this at all." On January 8, 2026, after markets closed, Beta Bionics reported an unexpected miss on new iLet patient starts. According to the underlying complaint, report disclosed that facts previously reported by the Capitol Forum in December – that Beta Bionics had received over 18,000 complaints out of less than 30,000 patients and failed to investigate, report to the FDA, or take corrective action – were credible and impacted Beta Bionics' performance. On this news, the price of Beta Bionics common stock dropped 37%, according to the complaint.

On January 30, 2026, Beta Bionics filed a Form 8-K that disclosed that the FDA had sent Beta Bionics a warning letter connected to its earlier Form 483. It is alleged that Beta Bionics conceded that the FDA's concerns were more serious than the minor difference in reporting-rule interpretation Beta Bionics had previously acknowledged. Then, on February 24, 2026, the FDA allegedly released the warning letter to the public that allegedly contradicted Beta Bionics' prior disclosure of the FDA's concerns – and the underlying issues with iLet – making clear that any malfunction that could be life threatening must be reported to the FDA. The complaint further alleges the warning letter elaborated that any hypoglycemia requiring medical intervention was reportable because any such episode, even if resolved by giving a patient candy, raises t...